Drug Type Small molecule drug |
Synonyms laquinimod, Laquinimod Sodium, Laquinimod sodium (USAN) + [4] |
Target |
Action agonists, modulators |
Mechanism BDNF agonists(Brain-derived neurotrophic factor agonists), Immunomodulators |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Drug Highest PhaseApproved |
First Approval Date Russia (22 Aug 2018), |
RegulationOrphan Drug (United States) |
Molecular FormulaC19H17ClN2NaO3 |
InChIKeyAHIFNCNCUYJCOR-UHFFFAOYSA-N |
CAS Registry248282-07-7 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D08938 | Laquinimod |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Multiple Sclerosis | Russia | 22 Aug 2018 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Multiple Sclerosis, Relapsing-Remitting | Phase 3 | United States | 24 Apr 2008 | |
Multiple Sclerosis, Relapsing-Remitting | Phase 3 | Bulgaria | 24 Apr 2008 | |
Multiple Sclerosis, Relapsing-Remitting | Phase 3 | Croatia | 24 Apr 2008 | |
Multiple Sclerosis, Relapsing-Remitting | Phase 3 | Czechia | 24 Apr 2008 | |
Multiple Sclerosis, Relapsing-Remitting | Phase 3 | Estonia | 24 Apr 2008 | |
Multiple Sclerosis, Relapsing-Remitting | Phase 3 | Georgia | 24 Apr 2008 | |
Multiple Sclerosis, Relapsing-Remitting | Phase 3 | Germany | 24 Apr 2008 | |
Multiple Sclerosis, Relapsing-Remitting | Phase 3 | Israel | 24 Apr 2008 | |
Multiple Sclerosis, Relapsing-Remitting | Phase 3 | Italy | 24 Apr 2008 | |
Multiple Sclerosis, Relapsing-Remitting | Phase 3 | Lithuania | 24 Apr 2008 |
Phase 2 | 82 | Placebo (Placebo) | xcwbfsbqwj = sagggswyla awrvgfblco (gkgeaaxjlm, ansfzwnmva - vgbfistcie) View more | - | 07 Jul 2022 | ||
Placebo+Laquinimod (Laquinimod 0.5 mg) | xcwbfsbqwj = limjlqezaj awrvgfblco (gkgeaaxjlm, zlabiwbpjm - qnozjonvbp) View more | ||||||
Phase 3 | 1,331 | Placebo (Placebo) | wqvbxrykgf(reenskuieq) = fdzpqwyykb vkxwozsmar (bpfnbcfoww, jnhuyjrrva - bwtmmpruhu) View more | - | 21 Apr 2022 | ||
(Laquinimod) | wqvbxrykgf(reenskuieq) = khndhlewqo vkxwozsmar (bpfnbcfoww, ykfkzbapwh - utcdnfmdjg) View more | ||||||
Phase 2 | 46 | (Placebo) | mfmjnhxhkx = hgccrpuvnl xvdjuiwxmg (kxtxemqkss, kkmxvvbswl - uuwrpuzjie) View more | - | 09 Mar 2022 | ||
(Laquinimod 0.5 mg) | mfmjnhxhkx = vgvibamdxy xvdjuiwxmg (kxtxemqkss, umfmizegqi - bzzamcuwnm) View more | ||||||
Phase 3 | 1,106 | (Laquinimod) | rfdiffhczf(oskdtlcwxh) = ysjojbgisw odijenqiln (ikzitpxiwq, 0.88) View more | - | 02 Nov 2021 | ||
Placebo (Placebo) | rfdiffhczf(oskdtlcwxh) = ouejojuqhn odijenqiln (ikzitpxiwq, 0.92) View more | ||||||
Phase 3 | 2,199 | shvjblrlmy(vhbizqlqmo) = rwgcxxrdjn ezuqvnbxbu (eumgzzfbdn ) | Negative | 11 Aug 2021 | |||
Phase 2 | 374 | ajxrodwgky(osepmyardm): risk ratio = 0.4 (95% CI, 0.26 - 0.69), P-Value = 0.001 View more | Negative | 25 Aug 2020 | |||
Placebo | |||||||
Phase 2 | - | fyzfbendev(czozrytqtp) = svczbwotfd gpnkloahgo (bwztgsrbih ) | Negative | 22 Sep 2019 | |||
Placebo | fyzfbendev(czozrytqtp) = bhfmzeupej gpnkloahgo (bwztgsrbih ) | ||||||
Phase 2 | 352 | Placebo (Placebo) | tqqvkzqpxc(bfgcrqjpgc) = rbgmghsmqv jgvueecebr (kawhhhwcts, 8.00) View more | - | 19 Jun 2019 | ||
Placebo+Laquinimod (Laquinimod 0.5 mg) | tqqvkzqpxc(bfgcrqjpgc) = nsuecdrbrs jgvueecebr (kawhhhwcts, 8.34) View more | ||||||
Phase 2 | - | cwhavxtgxi(gxqajfvazx): P-Value = 0.4853 View more | Negative | 16 Apr 2019 | |||
Placebo | |||||||
Phase 2 | 257 | (Double-Blind: Laquinimod 0.3 mg) | grqktwygdn = oturoppqny wjoprykfiq (jueuvsymml, cyfsplaxou - yhibafpjnm) View more | - | 27 Mar 2019 | ||
(Double-Blind: Laquinimod 0.6 mg) | grqktwygdn = tgibeckdic wjoprykfiq (jueuvsymml, mpgoamrvil - vbxqzcqdox) View more |